@article {107857,
	title = {A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA).},
	journal = {Blood},
	volume = {123},
	year = {2014},
	month = {2014 Mar 6},
	pages = {1447-54},
	abstract = {<p>Randomized comparison data on the efficacy and safety of deferasirox for myocardial iron removal in transfusion dependent patients are lacking. CORDELIA was a prospective, randomized comparison of deferasirox (target dose 40 mg/kg per day) vs subcutaneous deferoxamine (50-60 mg/kg per day for 5-7 days/week) for myocardial iron removal in 197 β-thalassemia major patients with myocardial siderosis (T2* 6-20 milliseconds) and no signs of cardiac dysfunction (mean age, 19.8 years). Primary objective was to demonstrate noninferiority of deferasirox for myocardial iron removal, assessed by changes in myocardial T2* after 1 year using a per-protocol analysis. Geometric mean (Gmean) myocardial T2* improved with deferasirox from 11.2 milliseconds at baseline to 12.6 milliseconds at 1 year (Gmeans ratio, 1.12) and with deferoxamine (11.6 milliseconds to 12.3 milliseconds; Gmeans ratio, 1.07). The between-arm Gmeans ratio was 1.056 (95\% confidence interval [CI], 0.998, 1.133). The lower 95\% CI boundary was greater than the prespecified margin of 0.9, establishing noninferiority of deferasirox vs deferoxamine (P = .057 for superiority of deferasirox). Left ventricular ejection fraction remained stable in both arms. Frequency of drug-related adverse events was comparable between deferasirox (35.4\%) and deferoxamine (30.8\%). CORDELIA demonstrated the noninferiority of deferasirox compared with deferoxamine for myocardial iron removal. This trial is registered at <a href="http://www.clinicaltrials.gov" title="www.clinicaltrials.gov">www.clinicaltrials.gov</a> as $\#$NCT00600938.</p>
},
	keywords = {Adolescent, Adult, Benzoates, beta-Thalassemia, Child, Deferoxamine, Female, Ferritins, Heart, Humans, Iron, Iron Chelating Agents, Iron Overload, Male, Medication Adherence, Myocardium, Treatment Outcome, Triazoles, Troponin T, Young Adult},
	issn = {1528-0020},
	doi = {10.1182/blood-2013-04-497842},
	author = {Dudley J. Pennell and John B. Porter and Piga, Antonio and Lai, Yongrong and Amal El-Beshlawy and Belhoul, Khawla M and Mohsen Elalfy and Yesilipek, Akif and Kilin{\c c}, Yurdanur and Lawniczek, Tomasz and Dany Habr and Weisskopf, Marianne and Zhang, Yiyun and Yesim Aydinok}
}
